|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
TW201402124A
(zh)
*
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
CA2732437C
(en)
|
2008-08-01 |
2017-11-21 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
|
ES2545275T3
(es)
|
2008-11-06 |
2015-09-09 |
Ventirx Pharmaceuticals, Inc. |
Métodos de síntesis de derivados de benzazepinas
|
|
CN105669552A
(zh)
*
|
2009-08-18 |
2016-06-15 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
|
CN105669553A
(zh)
*
|
2009-08-18 |
2016-06-15 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
|
US9950062B2
(en)
|
2009-09-02 |
2018-04-24 |
Glaxosmithkline Biologicals Sa |
Compounds and compositions as TLR activity modulators
|
|
CN107029223A
(zh)
|
2010-05-26 |
2017-08-11 |
西莱克塔生物科技公司 |
合成纳米载体联合疫苗
|
|
JP2013538217A
(ja)
|
2010-09-01 |
2013-10-10 |
ノバルティス アーゲー |
不溶性金属塩への免疫増強物質の吸着
|
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
|
MX346387B
(es)
*
|
2011-01-12 |
2017-03-02 |
Ventirx Pharmaceuticals Inc |
Benzoazepinas sustituidas como moduladores de receptores tipo toll.
|
|
CN103533954B
(zh)
|
2011-03-02 |
2015-09-09 |
诺华股份有限公司 |
含较低剂量的抗原和/或佐剂的联合疫苗
|
|
SG11201400210RA
(en)
|
2011-09-01 |
2014-03-28 |
Novartis Ag |
Adjuvanted formulations of staphylococcus aureus antigens
|
|
AU2013229465A1
(en)
|
2012-03-07 |
2014-09-04 |
Novartis Ag |
Adjuvanted formulations of rabies virus immunogens
|
|
WO2013131983A1
(en)
|
2012-03-07 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
|
CA2866406A1
(en)
|
2012-03-08 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of booster vaccines
|
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
BR112015005056A2
(pt)
|
2012-09-06 |
2017-11-21 |
Novartis Ag |
vacinas de combinação com sorogrupo b meningococcus e d/t/p
|
|
US9868955B2
(en)
|
2012-09-29 |
2018-01-16 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
EP2906239A1
(en)
|
2012-10-12 |
2015-08-19 |
GlaxoSmithKline Biologicals SA |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
|
US9827190B2
(en)
|
2013-02-01 |
2017-11-28 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
|
|
JP2016521282A
(ja)
|
2013-05-10 |
2016-07-21 |
ノバルティス アーゲー |
インフルエンザワクチンにおけるナルコレプシーのリスクの回避
|
|
EP3092256B1
(en)
|
2014-01-10 |
2022-05-18 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
|
MX377794B
(es)
|
2014-03-26 |
2025-03-10 |
Glaxosmithkline Biologicals Sa |
Antigenos estafilococicos mutantes.
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
DK4001311T3
(da)
|
2014-07-09 |
2026-02-02 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
SG11201606876RA
(en)
|
2015-03-04 |
2016-10-28 |
Gilead Sciences Inc |
Toll like receptor modulator compounds
|
|
CA2986494A1
(en)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Il-23-p19 vaccines
|
|
EP3319988A1
(en)
|
2015-07-07 |
2018-05-16 |
Affiris AG |
Vaccines for the treatment and prevention of ige mediated diseases
|
|
MA42684A
(fr)
|
2015-08-26 |
2018-07-04 |
Gilead Sciences Inc |
Modulateurs deutérés du récepteur toll
|
|
US20180263985A1
(en)
|
2015-09-15 |
2018-09-20 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
MX383893B
(es)
|
2015-11-02 |
2025-03-14 |
Ventirx Pharmaceuticals Inc |
Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
|
|
JP6732915B2
(ja)
|
2015-12-15 |
2020-07-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒト免疫不全ウイルス中和抗体
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
ES2969239T3
(es)
|
2016-05-27 |
2024-05-17 |
Gilead Sciences Inc |
Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
SI3507276T1
(sl)
|
2016-09-02 |
2022-01-31 |
Gilead Sciences, Inc. |
Spojine modulatorja toličnih receptorjev
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
UY37581A
(es)
|
2017-02-02 |
2018-08-31 |
Gilead Sciences Inc |
Compuestos para el tratamiento de la infección por virus de la hepatitis b
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
FI3641771T3
(fi)
|
2017-06-23 |
2026-08-11 |
Birdie Biopharmaceuticals Inc |
Farmaseuttisia koostumuksia
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
TW202024061A
(zh)
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
KR102891807B1
(ko)
|
2017-08-22 |
2025-12-01 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
CA3084667A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019161017A1
(en)
|
2018-02-15 |
2019-08-22 |
Gilead Sciences, Inc. |
Pyridine derivatives and their use for treating hiv infection
|
|
KR102847339B1
(ko)
|
2018-02-16 |
2025-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
IL317993B2
(en)
|
2018-07-03 |
2025-11-01 |
Gilead Sciences Inc |
Antibodies directed against HIV gp120 and methods of use
|
|
AU2019297428C1
(en)
|
2018-07-06 |
2023-03-23 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
CN112384505B
(zh)
|
2018-07-06 |
2025-05-27 |
吉利德科学公司 |
治疗性的杂环化合物
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
CA3103522C
(en)
|
2018-07-16 |
2023-11-21 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
SG11202101980VA
(en)
|
2018-09-12 |
2021-03-30 |
Silverback Therapeutics Inc |
Methods and composition for the treatment of disease with immune stimulatory conjugates
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
EP3873608A1
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
EP4371987B9
(en)
|
2018-10-31 |
2025-11-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
CN113574063B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸及其前药
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
KR20240151256A
(ko)
|
2019-03-22 |
2024-10-17 |
길리애드 사이언시즈, 인코포레이티드 |
가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
MX2021015533A
(es)
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
AU2020315598B2
(en)
|
2019-07-16 |
2024-12-12 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
JP2022544543A
(ja)
|
2019-08-15 |
2022-10-19 |
シルバーバック セラピューティックス インコーポレイテッド |
ベンザゼピンコンジュゲートの製剤およびその使用
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
HRP20241379T1
(hr)
|
2019-09-30 |
2024-12-20 |
Gilead Sciences, Inc. |
Cjepiva za hbv i postupci za liječenje hbv
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
CN114599652B
(zh)
*
|
2019-10-31 |
2024-07-12 |
豪夫迈·罗氏有限公司 |
用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
EP4061816A1
(en)
|
2019-11-19 |
2022-09-28 |
F. Hoffmann-La Roche AG |
Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
|
|
CA3157275C
(en)
|
2019-11-26 |
2026-02-10 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
US12410418B2
(en)
|
2019-12-06 |
2025-09-09 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
KR102987126B1
(ko)
|
2020-03-20 |
2026-07-07 |
길리애드 사이언시즈, 인코포레이티드 |
4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
|
|
JP7564888B2
(ja)
|
2020-05-01 |
2024-10-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
|
|
EP4153181B1
(en)
|
2020-05-21 |
2026-07-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
TWI858267B
(zh)
|
2020-06-25 |
2024-10-11 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
KR20230047361A
(ko)
|
2020-07-01 |
2023-04-07 |
아르스 파마슈티컬스 인크. |
항-asgr1 항체 접합체 및 이의 용도
|
|
LT4192474T
(lt)
|
2020-08-07 |
2025-11-25 |
|
Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CN116437958A
(zh)
|
2020-11-11 |
2023-07-14 |
吉利德科学公司 |
鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
US20240269142A1
(en)
|
2021-05-13 |
2024-08-15 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
FI4440702T3
(fi)
|
2021-12-03 |
2025-08-08 |
Gilead Sciences Inc |
Terapeuttisia yhdisteitä hiv-virusinfektiota varten
|
|
AU2022399845B2
(en)
|
2021-12-03 |
2026-03-26 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
AU2022403012B2
(en)
|
2021-12-03 |
2026-02-12 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TWI856796B
(zh)
|
2022-04-06 |
2024-09-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
CN119768183A
(zh)
|
2022-08-26 |
2025-04-04 |
吉利德科学公司 |
用于广泛中和抗体的给药和安排方案
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024076915A1
(en)
|
2022-10-04 |
2024-04-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
EP4698174A1
(en)
|
2023-04-19 |
2026-02-25 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024249573A1
(en)
|
2023-05-31 |
2024-12-05 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
TW202448483A
(zh)
|
2023-05-31 |
2024-12-16 |
美商基利科學股份有限公司 |
用於ｈｉｖ之治療性化合物
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
CN122295099A
(zh)
|
2023-07-28 |
2026-06-26 |
吉利德科学公司 |
用于治疗和预防hiv的来那卡帕韦的每周方案
|
|
AU2023462614A1
(en)
|
2023-08-23 |
2026-03-19 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
AU2024360779A1
(en)
|
2023-10-11 |
2026-04-16 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
IL327206A
(en)
|
2023-10-11 |
2026-05-01 |
Gilead Sciences Inc |
Bridged tricyclic carbamoylpyridone compounds and their uses
|
|
KR20260093341A
(ko)
|
2023-10-11 |
2026-06-19 |
길리애드 사이언시즈, 인코포레이티드 |
가교 트리시클릭 카르바모일피리돈 화합물 및 이의 용도
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025184447A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20250333424A1
(en)
|
2024-03-01 |
2025-10-30 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
WO2025184452A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
TW202608468A
(zh)
|
2024-05-13 |
2026-03-01 |
美商基利科學股份有限公司 |
組合療法
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025260028A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026076265A1
(en)
|
2024-10-03 |
2026-04-09 |
Gilead Sciences, Inc. |
Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|